[18F]MC225 is a special type of imaging agent used in this clinical trial. It helps doctors see how a protein called P-glycoprotein is working in the brain. This protein is important because it helps protect the brain by pumping out harmful substances. In people with neurodegenerative diseases like Alzheimer’s, Mild Cognitive Impairment, and Parkinson’s, this protein might not work properly. By using [18F]MC225, doctors can take pictures of the brain and see how well this protein is functioning. This can help them understand more about these diseases and how they affect the brain. The information gathered from these images can be crucial for developing better treatments in the future.

Parkinson’s Disease – Parkinson’s Disease is a progressive neurological disorder that affects movement. It is characterized by tremors, stiffness, and difficulty with balance and coordination. The disease progresses gradually, often starting with a barely noticeable tremor in one hand. As it advances, individuals may experience slower movement, muscle rigidity, and impaired posture. Over time, speech may become soft or slurred, and automatic movements such as blinking or smiling may decrease. The progression varies among individuals, with symptoms worsening over time.

Alzheimer’s Disease – Alzheimer’s Disease is a progressive neurodegenerative disorder that affects memory and cognitive function. It begins with mild memory loss and confusion, often mistaken for normal aging. As the disease progresses, individuals may experience significant memory impairment, difficulty in recognizing familiar people, and challenges in communication. Over time, it leads to severe cognitive decline, affecting the ability to perform daily tasks. Behavioral changes, such as mood swings and disorientation, are common as the disease advances. The progression is gradual, with symptoms worsening over several years.

Mild Cognitive Impairment – Mild Cognitive Impairment (MCI) is a condition characterized by noticeable changes in cognitive abilities, such as memory and thinking skills, that are greater than expected for a person’s age. It is considered an intermediate stage between normal age-related cognitive decline and more serious conditions like dementia. Individuals with MCI may experience forgetfulness, difficulty concentrating, and challenges in decision-making. Unlike dementia, these changes do not significantly interfere with daily life and activities. MCI can remain stable, improve, or progress to dementia over time. The progression varies, and not all individuals with MCI will develop more severe cognitive disorders.